Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA adverse event reporting system (FAERS)

Journal of Biomedical Informatics

Volumn 47, Issue , 2014, Pages 171-177

  Xu, Rong ^a   Wang, QuanQiu ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b ThinTek LLC   (United States)

Author keywords

Cardiotoxicity; Data mining; Personalized medicine; Post market drug safety surveillance; Targeted cancer therapy

Indexed keywords

COMMERCE; DATA MINING; DRUG PRODUCTS; MARKETING; PATIENT TREATMENT; SIGNAL FILTERING AND PREDICTION;

CARDIOTOXICITY; CARDIOVASCULAR EVENT; DRUG SAFETY; FILTERING ALGORITHM; NAMED ENTITY RECOGNITION; PERSONALIZED MEDICINES; TARGETED CANCER THERAPY; TREATMENT OUTCOMES;

DISEASES;

ANTINEOPLASTIC AGENT;

ACCURACY; ALGORITHM; ARTICLE; CANCER PATIENT; CARDIOVASCULAR DISEASE; COMORBIDITY; DATA EXTRACTION; DRUG SURVEILLANCE PROGRAM; FILTRATION; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; SIGNAL DETECTION;

CARDIOTOXICITY; DATA MINING; PERSONALIZED MEDICINE; POST-MARKET DRUG SAFETY SURVEILLANCE; TARGETED CANCER THERAPY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; ANTINEOPLASTIC AGENTS; AUTOMATIC DATA PROCESSING; CARDIOVASCULAR DISEASES; DATA MINING; DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84895421624     PISSN: 15320464     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbi.2013.10.008     Document Type: Article

References (34)

1. Cleeland C.S., Allen J.D., Roberts S.A., Brell J.M., Giralt S.A., Khakoo A.Y., et al. Reducing the toxicity of cancer therapy: recognizing needs, taking action. Nat Rev Clin Oncol 2012.
2. Keefe D.M., Bateman E.H. Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol 2011, 9(2):98-109.
3. Ewer M.S., Ewer S.M. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 2010, 7(10):564-575.
4. Schmidinger M., Zielinski C.C., Vogl U.M., Bojic A., Bojic M., Schukro C., et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011, 13(1):1-10.
5. Mellor H.R., Bell A.R., Valentin J.P., Roberts R.R. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol Sci 2011, 120(1):14-32.
6. Moslehi J., Cheng S. Cardio-oncology: it takes two to translate. Sci Transl Med 2013, 5(187):187fs20.
7. Gibb S. Toxicity testing in the 21st century. A vision and a strategy. Reprod Toxicol 2008, 25:136-138.
8. Raschi E., De Ponti F. Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology. Intern Emerg Med 2012, 7(2):113-131.
9. Pujol A., Mosca R., Farrés J., Aloy P. Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci 2010, 31(3):115-123.
10. Turteltaub K.W., Davis M.A., Burns-Naas L.A., Lawton M.P., Clark A.M., Reynolds J.A. Identification and elucidation of the biology of adverse events: the challenges of safety assessment and translational medicine. Clin Cancer Res 2011, 17(21):6641-6645.
11. Xu R, Wang Q. Toward creation of a cancer drug toxicity knowledge base: automatically extracting cancer drug side effect relationships from literature. J Am Med Inform Assoc 2013. doi: [published online first: 18.05.13]. doi:10.1136/amiajnl-2012-001584.
12. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm.
13. http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted.
14. Chen M.H., Kerkela R., Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008, 118:84-95.
15. Ravaud A. How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. Ann Oncol 2009, 20(Suppl. 1):i7-i12.
16. Bonura F., Di Lisi D., Novo S., D'Alessandro N. Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist oncologist and cardiologist. Cardiovasc Toxicol 2012, 12(2):93-107.
17. Force T., Kolaja K.L. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov 2011, 10(2):111-126.
18. Liebler D.C., Guengerich F.P. Elucidating mechanisms of drug-induced toxicity. Nat Rev Drug Discov 2005, 4(5):410-420.
19. Campillos M., Kuhn M., Gavin A.C., Jensen L.J., Bork P. Drug target identification using side-effect similarity. Science 2008, 321(5886):263-266.
20. Seruga B., Sterling L., Wang L., Tannock I.F. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol 2011, 29:174-185.
21. Richey E.A., Lyons E.A., Nebeker J.R., Shankaran V., McKoy J.M., Luu T.H., et al. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?. J Clin Oncol 2009, 27:4398-4405.
22. Harpaz R., DuMouchel W., Shah N.H., Madigan D., Ryan P., Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther 2012, 91(6):1010-1021.
23. Evans S.J.W., Waller P.C., Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001, 10(6):483-486.
24. Harpaz R., Vilar S., DuMouchel W., Salmasian H., Haerian K., Shah N.H., et al. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J Am Med Inform Assoc 2013, 20(3):413-419.
25. Wilson A.M., Thabane L., Holbrook A. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol 2004, 57(2):127-134.
26. Bate A., Evans S.J.W. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 2009, 18(6):427-436.
27. Stephenson W.P., Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf 2007, 16(4):359-365.
28. Brown E.G., Wood L., Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999, 20(2):109-117.
29. Manning C.D., Raghavan P., Schütze H. Introduction to information retrieval 2008, vol. 1. Cambridge University Press, Cambridge.
30. http://dailymed.nlm.nih.gov/dailymed/downloadLabels.cfm.
31. Bodenreider O. The unified medical language system (UMLS): integrating biomedical terminology. Nucleic Acids Res 2004, 32(Suppl. 1):D267-D270.
32. Friedman C. Discovering novel adverse drug events using natural language processing and mining of the electronic health record. Artif Intell Med 2009, 1-5. [Berlin Heidelberg: Springer].
33. White R.W., Tatonetti N.P., Shah N.H., Altman R.B., Horvitz E. Web-scale pharmacovigilance: listening to signals from the crowd. J Am Med Inform Assoc 2013, 20(3):404-408.
34. Leaman R, Wojtulewicz L, Sullivan R, Skariah A, Yang J, Gonzalez G. Towards internet-age pharmacovigilance. Extracting adverse drug reactions from user posts to health-related social networks. In: Proceedings of the 2010 workshop on biomedical natural language processing. Association for Computational Linguistics; July, 2010. p. 117-25.